Shots:
- VelaVigo Bio has granted Ollin Biosciences an exclusive license to develop, manufacture & commercialize VBS-102 worldwide, except Greater China, where VelaVigo will maintain its rights
- As per the deal, VelaVigo will receive an upfront payment along with development, regulatory, & commercial milestones in cash & equity, making an aggregate of ~$440M, plus tiered royalties based on sales
- Additionally, VelaVigo to advance its fully owned lead FIC/BIC bispecific ADC into a US trial in 2025, & will showcase 5 additional FIC/BIC molecule data at future conferences to explore global partnership opportunities
Ref: Prnewswire | Image: VelaVigo
Related News:- BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
